STAMFORD, Conn., Feb. 9 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. announced today that it has retained Jonathan Foltz, CFA, the Company's former Director of Operations, as an advisor to its new management team. Mr. Foltz has approximately 17 years experience with Delcath Systems and was instrumental in assisting the company in achieving several major milestones, including obtaining Fast-Track status as well a Special Protocol Assessment for its pivotal Phase III Melphalan trial being conducted at the National Cancer Institute.
Richard Taney, Chief Executive Officer of Delcath Systems, stated, "We are pleased that Jonathan has agreed to return to Delcath Systems as an advisor. His efforts will be focused on key initiatives that have either been identified by the new management team or which are already underway at Delcath. Jonathan's deep understanding of the company's operations and objectives will be a valuable resource as we continue to aggressively pursue the development and advancement of our proprietary drug delivery device."
Mr. Foltz stated, "I am excited to be working with Richard. He shares my belief in the promise of this technology and I look forward to assisting him in expanding the applications for this device and improving the technology and intellectual property position of Delcath. While there are challenges ahead, the company is taking the steps necessary to move towards FDA approval and development of a robust product pipeline."
About Delcath Systems, Inc.
Delcath Systems is a developer of percutaneous isolated perfusion technology for organ or region-specific delivery of therapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, http://www.delcath.com.
This release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Company Contact: Delcath Systems, Inc. Richard Taney 203-323-8668 www.delcath.com Media Contact: Lewis Goldberg KCSA Worldwide (212) 896-1216 lgoldberg@kcsa.com Investor Contacts: Todd Fromer / Garth Russell KCSA Worldwide (212) 896-1215 / (212) 896-1250 tfromer@kcsa.com / grussell@kcsa.com
Delcath Systems, Inc.CONTACT: Company Contact - Richard Taney of Delcath Systems, Inc.,+1-203-323-8668; or Media Contact - Lewis Goldberg, +1-212-896-1216,lgoldberg@kcsa.com; or Investor Contacts - Todd Fromer, +1-212-896-1215,tfromer@kcsa.com, or Garth Russell, +1-212-896-1250, grussell@kcsa.com, allof KCSA Worldwide, for Delcath Systems, Inc.
Web site: http://www.delcath.com/
